I don't agree. It will sink lower on momentum. JUNO has benefited from the appearance of looking like it was bulletproof unlike a few dozen of previous biotech high fliers who lost 95% of their value in the past year. It will go lower. I estimate mid 18s before a rally to low 20s.
From a rough reading of the latest filing it seems Cowen is set to get about $4.2 million. If there's no better deal and all the employees are taken in by Pfizer, I think we could expect about a 7-8m shareholders' equity on this company.
Of course, if they somehow manage to sell the tax credits for a good price, that will change things. Looks doubtful here though.
No it did not.... you are regurgitating (your own?) rumor. What they objected to was a limited objection based on a fear that their contracts with BIND would not survive the sale.
When you make a bid, you don't "object" to another bid.
They can continue the trial, but they will likely have to start with new patients (after an FDA meeting, and who knows how long that will take) because the results will be muddied.
Just the idea that they are not set to sell the negative retained earnings as an asset makes me very upset. Maybe it's just not applicable here.
They will not start over the P3. They will file an NDA with an accelerated approval request if they can find any good information in their data. Hopefully the FDA will start considering that in 2017, because this year it seems that the FDA is unable or unwilling to approve much without bribes, etc.
Assuming the treasuries are not part of the assets, you are looking at about $12.5m equity value left over, minus operating expenses for this quarter, and that could be maybe 4-5m.. so this is not the floor.
* It's possible they will find another bidder, though this is not likely given that 130 entities were contacted and only Pfizer made an initial bid.
* Maybe they will find someone to sell the accumulated negative retained earnings to (which should have ideally been just Pfizer...) and that will add to the value tremendously.
I don't really see anyone doing that. You should really read the first few pages in the motion on July 1 which is available at casesDOTprimeclerkDOTcom/BIND/Home-DocketInfo.
There is a lot to cover here.... have fun! I certainly did.
Yes, it makes a difference, and not just on the Yahoo MB. However, not like how you think. I ran a little masochistic experiment on myself by writing some articles on KMPH. The stock fell before my articles were written from about 17 to about 8. My articles potentially caused more volume than normal and the price hit 7.30 even after unpleasant news hit that confirmed the cause of the 17-8 drop. Another news event that further confirmed the news finally caused retail holders to sell out and lose money, currently crashing the stock to under 4.
I do not take away from the letter that it does, merely that there was no difference from placebo.